Jazz Pharmaceuticals shared on LinkedIn:
“News for U.S. media and investors: At ESMO26 we’re presenting our latest Phase 3 data, including 3-year survival follow-up results, in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
These results reflect our momentum in GEA and reinforce our continued commitment to bring meaningful treatment options to the people living with cancer and their families.”
You can also read: RAMIRIS Trial at ESMO 2026: FOLFIRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab in Advanced Gastroesophageal Adenocarcinoma
